Previous close | 36.89 |
Open | 37.03 |
Bid | 37.44 x 300 |
Ask | 37.56 x 1100 |
Day's range | 36.97 - 38.49 |
52-week range | 33.79 - 63.57 |
Volume | |
Avg. volume | 1,430,919 |
Market cap | 4.472B |
Beta (5Y monthly) | 1.92 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.18 |
Earnings date | 01 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 57.79 |
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Visium HD Spatial Gene Expression product. This assay enables researchers to measure the whole transcriptome from FFPE tissue sections at single cell-scale resolution.
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applications. These new products expand the breadth of the Xenium single cell spatial analysis menu.
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping the first two products powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3. GEM-X is the next generation of the company's leading single cell technology architecture and is built on a new and improved microfluidic chip design, featuring the latest technological advancements and optimized re